News & Updates
Filter by Specialty:
Long-term KEEPsAKE data show sustained improvements with risankizumab for PsA
The humanized immunoglobulin G1 monoclonal antibody risankizumab conferred long-term benefit for individuals with active psoriatic arthritis (PsA) who had inadequate responses to biologic and conventional synthetic DMARDs* (csDMARDs), according to the open-label extension (OLE) phase findings of the KEEPsAKE 1 and 2 trials presented at EADV 2021.
Long-term KEEPsAKE data show sustained improvements with risankizumab for PsA
08 Oct 2021
Neurovascular bundle sparing boosts postoperative sexual function in prostate cancer patients
The width of the spared neurovascular bundle (NVB) is an important indicator of postoperative sexual function after robot-assisted laparoscopic prostatectomy for prostate cancer, a recent study has found. These findings point to NVB as an easy intraoperative marker for assessing postoperative outcomes.
Neurovascular bundle sparing boosts postoperative sexual function in prostate cancer patients
08 Oct 2021
Depression and suicidal ideation high in Hong Kong doctors
A cross-sectional study in Hong Kong finds high prevalence of depressive symptoms and suicidal ideation among doctors in Hong Kong, although many remain undiagnosed of depression.
Depression and suicidal ideation high in Hong Kong doctors
08 Oct 2021
ADT-docetaxel-abiraterone: A winning combo for mCSPC
Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.
